Smith & Nephew plc (SNN) is a publicly traded Healthcare sector company. As of May 21, 2026, SNN trades at $30.58 with a market cap of $12.91B and a P/E ratio of 0.00. SNN moved +0.44% today. Year to date, SNN is -6.99%; over the trailing twelve months it is +5.44%. Its 52-week range spans $23.69 to $38.79. Analyst consensus is neutral with an average price target of $32.32. Rallies surfaces SNN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Smith & Nephew slips after Q1 growth narrowly misses, despite new $500M buyback: Smith & Nephew shares fell after its Q1 2026 trading update showed 3.1% underlying revenue growth to $1.501 billion, slightly below market expectations. The company reiterated full-year guidance and announced a new $500 million share buyback, but investors focused on softer-than-expected growth and U.S. knee implant weakness.
| Metric | Value |
|---|---|
| Price | $30.58 |
| Market Cap | $12.91B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.48% |
| 52-Week High | $38.79 |
| 52-Week Low | $23.69 |
| Volume | 4.07K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover SNN: 0 strong buy, 0 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $32.32.